Medexus Pharmaceuticals Reports Strong Q1 2026 Results Driven by GRAFAPEX Launch

The latest update is out from Medexus Pharmaceuticals Inc ( (TSE:MDP) ).

Medexus Pharmaceuticals reported fiscal Q1 2026 results with a net revenue of $24.6 million and a net income of $0.5 million. The company highlighted the positive market response to its new product, GRAFAPEX, which generated $3.0 million in net revenue and is expected to be accretive to cash flows by fiscal Q3 2026. Despite a decline in revenues from other products like Rupall due to generic competition, Medexus remains confident in GRAFAPEX’s potential to solidify its leadership in the allo-HSCT field, with significant formulary inclusions and orders from transplant centers.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Spark’s Take on TSE:MDP Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDP is a Neutral.

Medexus Pharmaceuticals shows strong financial performance and promising corporate developments, particularly with GRAFAPEX. However, technical indicators suggest caution, and valuation metrics are moderate. The company’s ability to manage liabilities and operational efficiency will be crucial for future performance.

To see Spark’s full report on TSE:MDP stock, click here.

More about Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on delivering strong performance across its portfolio of products in the United States and Canada. The company is currently emphasizing the US launch of GRAFAPEX, a treosulfan injection, which is expected to play a significant role in the allo-HSCT therapeutic field.

Average Trading Volume: 33,329

Technical Sentiment Signal: Sell

Current Market Cap: C$85.16M

For a thorough assessment of MDP stock, go to TipRanks’ Stock Analysis page.